Section 2-3 of the Bharat Biotech vaccine for children aged 2 to 18 years, the expert panel agrees

 The trial will be held at 525 people at AIIMS Delhi, AIIMS Patna and the Mediterranean Institute of Medical Sciences Nagpur.

After Canada and the United States, India will once again have a traditional corona vaccine of the same group for two to 18 years. According to official sources, the academic committee (SEC) of the Central Drugs Control Organization (CDSCO) on Tuesday approved the second and third Bharat Biotech covacin trials for those aged 2 to 18 years.

The trial will take place at 525 AIIMS Delhi, AIIMS Patna and the Mediterranean Institute of Medical Sciences Nagpur. A committee of academic experts considered Bharat Biotech's proposal in Hyderabad on Tuesday.

The second phase of the experimental data should be submitted to the Data Monitoring Board.

According to sources, the expert committee instructed the data monitoring and security board to make the second category of security information available to the company before seeking approval from the CDSCO in the third phase case. Earlier, the proposal was discussed at a meeting on February 24 and Barat Biotech was directed to introduce a clinical trial law.

The traditional covacin vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) is used for 18+ vaccination programs in the country.

Medication approved for adolescents ages 12 to 15 in the United States Earlier on Monday, the US Food and Drug Administration (US-FDA) approved the Pfizer-Bioentech corona vaccine for children aged 12 to 15 years. So far the vaccine has been given to people over the age of 16.

ગુજરાતીમાં વાંચવા માટે અહી ક્લિક કરો


Canada has already adopted this first childhood vaccine. This is the first country in the world to do so. It is said that immunization of children between the ages of 12 and 15 will pave the way for the opening of a large number of schools and summer camps in the United States.

Search This Website